Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have been assigned a consensus rating of “Moderate Buy” from the twenty analysts that are presently covering the firm, MarketBeat reports. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $49.94.

APLS has been the topic of several research analyst reports. Needham & Company LLC decreased their target price on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Evercore ISI raised shares of Apellis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, October 31st. Citigroup dropped their price objective on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Piper Sandler reduced their target price on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a report on Wednesday, November 6th. Finally, Mizuho dropped their price target on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, October 24th.

Institutional Trading of Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wolverine Asset Management LLC acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter worth approximately $27,000. True Wealth Design LLC bought a new position in Apellis Pharmaceuticals during the third quarter worth $27,000. Capital Performance Advisors LLP bought a new position in Apellis Pharmaceuticals during the third quarter worth $56,000. KBC Group NV boosted its holdings in Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after purchasing an additional 679 shares during the period. Finally, nVerses Capital LLC increased its stake in Apellis Pharmaceuticals by 300.0% during the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after purchasing an additional 2,100 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ APLS opened at $33.21 on Friday. The firm’s 50 day moving average price is $30.31 and its 200 day moving average price is $34.58. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The firm has a market cap of $4.13 billion, a P/E ratio of -16.36 and a beta of 0.94. Apellis Pharmaceuticals has a 1 year low of $24.34 and a 1 year high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. During the same quarter in the previous year, the company posted ($1.17) earnings per share. The business’s revenue for the quarter was up 78.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals will post -1.72 earnings per share for the current year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).